Akcea Therapeutics, Inc.

US Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan

After reporting the full dataset from the Phase III BALANCE study of olezarsen in familial chylomicronemia syndrome (FCS) at the American College of Cardiology meeting, Ionis Pharmaceuticals, Inc. t

Ionis Pharmaceuticals, Inc. took another step forward on its path to bringing its first wholly-owned drug to market without a partner on 26 September when it reported positive topline results from th

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis And Ionis Build On Earlier Akc